Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV vaccination in recurrent respiratory papillomatosis
2011-002667-14Phase 3Completed
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle in Laryngeal papilloma (RRP), sponsored by Institute of Hematology and Blood Transfusion. Primary endpoint: Occurrence or frequency of recurrences of laryngeal papillomatosis. Started Jun 2011; status: completed.
02
Drugs
quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle
03
Conditions
Laryngeal papilloma (RRP)
Beyond the preview
Go deeper on 2011-002667-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002667-14.